New combo therapy shows promise for Hard-to-Treat sarcomas
NCT ID NCT05488366
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-phase study tested whether combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) is feasible for people with advanced soft-tissue sarcoma that has spread or cannot be removed by surgery. Nine participants received the combination. The main goal was to see if patients could complete the treatment, and researchers also measured how well the tumors responded, including at sites not directly treated with radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.